New York City proposes $8.9 million for minors’ puberty drugs

The Oct. 6 notice names two potential vendors and sets an Oct. 16 deadline, as a federal Medicaid and CHIP funding rule takes effect Oct. 13.

New York City's Health Department moved on Oct. 6 to pay outside organizations an estimated $8,879,218 to prescribe puberty blockers and hormones to children through a negotiated acquisition rather than competitive sealed proposals. “There is a compelling need for gender-affirming care services that cannot be met timely by competitive sealed proposals,”¹ the department wrote in its City Record notice, PIN 81627N0004.

The notice names two potential vendors, Callen-Lorde and the Nonprofit Organization for Philanthropic Initiatives (NOPI), and other providers have until Oct. 16 to express interest². The proposed contracts would run three years, from Feb. 1, 2027 to June 30, 2029, with an option to renew for three more¹. The work is spelled out plainly: the notice says the contracts include "the prescription and administration of puberty-blockers and hormone replacement therapy to all minor patients for whom such services are medically necessary based on the prevailing standards of care." Gothamist reported the plan on Oct. 7³, six days before a federal rule takes effect on Oct. 13 barring federal Medicaid and CHIP funds from covering this care for minors⁴.

Nothing is signed. This is an intent to negotiate, and that is exactly why parents and taxpayers still have time to be heard.

The city's stated reason for skipping a competitive bid is speed: it says there is a compelling need that sealed proposals cannot meet in time¹. A negotiated acquisition is the legal mechanism, and choosing it is a decision, not an accident. Gothamist reports the procurement is the largest piece of a $15 million initiative the Mamdani administration announced in June².

The timing tells the rest. Gothamist reports that NYU Langone and Mount Sinai stopped providing this care to minors². The Justice Department said its probes concerned potential violations of federal health care laws. When two major systems walk away under federal scrutiny, the city's answer is to hire others to keep going, on an expedited track. Does a city that skips competitive bidding on puberty blockers for children owe parents a public explanation first?

The 2025 HHS review of 17 systematic reviews concluded that harms are significant, long-term and inadequately tracked; it also says the American Academy of Pediatrics and the Endocrine Society declined to contribute evidence. Family Brief's position is plain: no taxpayer funding for sex-change procedures, and parents have every right, and good reason, to resist puberty blockers and cross-sex hormones for their children. New York City met the hospitals' retreat with more public money, not more scrutiny.

Oct. 6The city published its procurement notice
Oct. 7Gothamist reported the plan
Oct. 13The federal funding rule takes effect
Oct. 16Deadline for other providers to express interest
Feb. 1, 2027Proposed contracts would begin

$8,879,218

estimated procurement value

$15 million

initiative total

The federal rule bars Medicaid and CHIP funding for covered services starting Oct. 13, while allowing up to six months of federal funding to taper medications for some youth already receiving them. Virginia's Medicaid agency has told providers it will no longer cover gender dysphoria services for Medicaid members under 18 or CHIP members under 19 for dates of service on or after that day⁵. Arizona, like Virginia led by a Democratic governor, has rewritten its prior authorization criteria so that hormone therapy and puberty blockers for patients under 19 are no longer covered under Medicaid, LGBTQ Nation reports⁴.

Other Democratic states went the other way. The rule does not stop a state from spending its own money, and Illinois has announced it will use state funds to preserve coverage through the end of its 2027 fiscal year. California has set up a state-funded mechanism of its own⁶. New York City is proposing a city-funded procurement for organizations providing these services to minors. It is decided in state capitols and city halls, in front of the parents whose taxes foot the bill.

The City Record notice says treatment will be provided consistent with state laws governing parental consent. Virginia Gov. Abigail Spanberger, through her spokesperson, called the federal policy a case of "targeting and using as pawns people who rely on Medicaid for their healthcare coverage, and in this case, children⁶."

Consent settles who may agree to a treatment. It does not settle who pays for it.

Professional judgment is the center of that case, and The Advocate notes that the American Medical Association and the American Academy of Pediatrics support access⁶. A mayor who calls this care lifesaving owes taxpayers that argument in public, not inside a procurement notice.

Between the Oct. 16 interest deadline and the Feb. 1, 2027 start, New York parents and taxpayers hold the only leverage they will get. Put the questions to the Health Department and Mayor Mamdani's office, in writing and at every public venue. How many minors would these contracts serve? What will each patient cost? And why is the city proposing to spend nearly $8.9 million in public money this way? Track the City Record for the next step under PIN 81627N0004¹. A city that chose speed over scrutiny owes the families paying for it those answers before the first contract starts, not after.

New York City proposes $8.9 million for minors’ puberty drugs

Sources